Boston Scientific launches next-gen pacemaker lead trial
Boston Scientific says the 1st patient is implanted with its next-generation Ingevity MRI-safe pacemaker leads.
The Marlborough, Mass.-based medical device company said a patient in Sweden was the first enrollee in the trial, which is aimed at proving the safety and effectiveness of the devices in treating slow heartbeats or bradycardia.
The new leads are likely to be paired with Boston Scientific's Ingenio pacemaker line, according to a press release. The company is hoping the data from the 1,000-patient trial will back regulatory nods in the U.S. and the European Union, according to the release.